Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review
- PMID: 37745189
- PMCID: PMC10516218
- DOI: 10.2147/NDT.S413371
Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review
Abstract
Evidence of comparative benefits of long-acting injectable (LAI) antipsychotics in Asian patients with schizophrenia has been inconsistent. This scoping review aimed to synthesize the current evidence in the past ten years and provide an overview of efficacy, safety, treatment adherence, patient attitudes, and healthcare resource utilization of LAI in this population. A systematic search was conducted with a pre-defined search strategy in six electronic databases including Chinese National Knowledge Infrastructure (CNKI), Wanfang, PubMed, Embase, CINAHL, and PsycArticles. A total of 46 studies were included, including 15 cohort studies, 13 single-arm trials, 10 randomized controlled trials, four mirror-image studies, three cross-sectional studies, and one controlled clinical trial. Paliperidone palmitate once-monthly injection (27/46) and risperidone LAI (14/46) were the most frequently investigated LAIs. Compared with oral antipsychotic medications (OAMs), LAIs demonstrated a lower rate of relapse/hospitalization and comparable improvement in efficacy. Adverse events (AEs) were similar between LAIs and OAMs, although types and incidence varied. Significant reduction in the length of hospitalization and number of outpatient visits/inpatient admission was observed after initiation of LAIs. These findings suggest that LAI demonstrated comparable efficacy and safety among Asian populations with schizophrenia in comparison to OAMs. Better adherence and lower relapse were observed in patients receiving LAIs from published evidence. Future research is warranted to better understand the comprehensive performance of LAI in specific population or context.
Keywords: Asian; long-acting injectable antipsychotics; schizophrenia; scoping review.
© 2023 Ma et al.
Conflict of interest statement
Zhang L, Ye C and Li X are employees of Xi’an Janssen Pharmaceutical Ltd. All other authors have no conflicts of interest to declare in relation to this study.
Figures
Similar articles
-
Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.J Manag Care Spec Pharm. 2015 Sep;21(9):754-68. doi: 10.18553/jmcp.2015.21.9.754. J Manag Care Spec Pharm. 2015. PMID: 26308223 Free PMC article.
-
Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.Curr Med Res Opin. 2016 Nov;32(11):1873-1881. doi: 10.1080/03007995.2016.1219706. Epub 2016 Aug 22. Curr Med Res Opin. 2016. PMID: 27479694
-
Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.J Clin Psychiatry. 2013 Oct;74(10):957-65. doi: 10.4088/JCP.13r08440. J Clin Psychiatry. 2013. PMID: 24229745
-
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.Lancet Psychiatry. 2021 May;8(5):387-404. doi: 10.1016/S2215-0366(21)00039-0. Epub 2021 Apr 13. Lancet Psychiatry. 2021. PMID: 33862018
-
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.Clin Ther. 2017 Oct;39(10):1972-1985.e2. doi: 10.1016/j.clinthera.2017.08.008. Epub 2017 Sep 15. Clin Ther. 2017. PMID: 28919292
Cited by
-
Outcomes of long-acting injectable antipsychotics use in pregnancy: A literature review.World J Psychiatry. 2024 Apr 19;14(4):582-599. doi: 10.5498/wjp.v14.i4.582. eCollection 2024 Apr 19. World J Psychiatry. 2024. PMID: 38659600 Free PMC article.
-
Efficacy and Safety of Once-Monthly Paliperidone Palmitate Long-Acting Injections in Chinese Patients with Early-, Mid-, and Late-Phase Schizophrenia: A Post-Hoc Analysis of Three Phase 4 Studies.CNS Drugs. 2025 Aug;39(8):795-805. doi: 10.1007/s40263-025-01194-4. Epub 2025 Jun 15. CNS Drugs. 2025. PMID: 40517352 Free PMC article.
-
In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan.JAMA Netw Open. 2024 Jun 3;7(6):e2417006. doi: 10.1001/jamanetworkopen.2024.17006. JAMA Netw Open. 2024. PMID: 38884998 Free PMC article.
-
Transformative Outcomes With Paliperidone Long-Acting Injection in Severe Treatment-Resistant Schizophrenia: A Case Report and Literature Review.Cureus. 2024 Aug 1;16(8):e65939. doi: 10.7759/cureus.65939. eCollection 2024 Aug. Cureus. 2024. PMID: 39221361 Free PMC article.
-
An analysis of the clinical application of paliperidone palmitate injection based on real-world.Front Pharmacol. 2025 Mar 26;16:1501701. doi: 10.3389/fphar.2025.1501701. eCollection 2025. Front Pharmacol. 2025. PMID: 40206056 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous